| 表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制 |
| |
| 引用本文： | 雷碧黠,张梦瑶,陈晓锐,梁蓓蓓,解伟,王华菁,李博华.表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制[J].药学实践杂志,2022,40(2):136-142. |
| |
| 作者姓名： | 雷碧黠 张梦瑶 陈晓锐 梁蓓蓓 解伟 王华菁 李博华 |
| |
| 作者单位： | 上海中医药大学研究生院, 上海 201203;原启生物科技(上海)有限责任公司, 上海 201203;上海健康医学院药学院，上海 201318;上海中医药大学研究生院, 上海 201203;上海健康医学院分子影像学重点实验室，上海 201318 |
| |
| 摘 要： | 目的 研究表没食子儿茶素没食子酸酯(EGCG)联合曲妥珠单抗对人表皮生长因子受体2(HER2)过表达乳腺癌细胞增殖的影响及其作用机制.方法 表达纯化曲妥珠单抗;用CCK-8细胞增殖检测试剂盒(CCK8)检测不同浓度EGCG、曲妥珠单抗及两药联用对HER2过表达乳腺癌细胞BT474、SK-BR-3的增殖抑制作用;用Wes...
|
| 关 键 词： | 表没食子儿茶素没食子酸酯 曲妥珠单抗 人表皮生长因子受体2过表达 乳腺癌 协同 增殖抑制 |
| 收稿时间： | 2021/12/11 0:00:00 |
| 修稿时间： | 2022/2/28 0:00:00 |
The effect and mechanism of epigallocatechol gallate combined with trastuzumab on the proliferation of HER2 overexpressing breast cancer cells |
| |
| LEI Bixi,ZHANG Mengyao,CHEN Xiaorui,LIANG Beibei,XIE Wei,WANG Huajing,LI Bohua.The effect and mechanism of epigallocatechol gallate combined with trastuzumab on the proliferation of HER2 overexpressing breast cancer cells[J].The Journal of Pharmaceutical Practice,2022,40(2):136-142. |
| |
| Authors: | LEI Bixi ZHANG Mengyao CHEN Xiaorui LIANG Beibei XIE Wei WANG Huajing LI Bohua |
| |
| Institution: | Graduated School , Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;Origin Cell Therapeutics, Shanghai 201203, China;School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China; Graduated School , Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China |
| |
| Abstract: | Objective To study the effect and mechanism of epigallocatechol gallate (EGCG) combined with trastuzu-mab on the proliferation of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer cells. Methods Trastuzumab was expressed and purified. The cell proliferation of HER2 overexpressing breast cancer cells BT474 and SK-BR-3 treated with trastuzumab, EGCG, or trastuzumab plus EGCG was evaluated by CCK8 assay. The effects of EGCG and trastuzumab on the expression of HER2, epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), protein kinase B (Akt), and their phosphorylated proteins in BT474 breast cancer cells were detected by Western blot. Results The results of cell proliferation assay indicated that EGCG and trastuzumab, alone or in combination, effectively inhibited the proliferation of BT-474 and SK-BR-3 cells. And within a certain concentration range, EGCG and trastuzumab showed a synergistic proliferation inhibitory effect on HER2 overexpressing breast cancer cells. Consistent with these results, Western blot results showed that trastuzumab and EGCG, alone or in combination significantly reduced the phosphorylation levels of Akt, MAPK, EGFR, and HER2 in BT474 cells. Moreover, the inhibition effect of EGCG plus trastuzumab was significantly more potent than either EGCG or trastuzumab. Conclusion EGCG and trastuzumab could synergistically inhibit the proliferation of HER2 overexpressing breast cancer cells, which may be related to the regulation of Akt and MAPK signaling pathways. |
| |
| Keywords: | EGCG trastuzumab HER2 overexpression breast cancer synergy proliferation inhibition |
|
| 点击此处可从《药学实践杂志》浏览原始摘要信息 |
| 点击此处可从《药学实践杂志》下载免费的PDF全文 |
|
